A standard 5-panel drug test for DOT-regulated industries does not automatically test for fentanyl. Under current rules, laboratories test DOT specimens for five drug classes: marijuana metabolites, cocaine metabolites, amphetamines, opioids, and PCP. In fact, per DOT, laboratories must not test DOT specimens for other drugs.
For many employers, that answer is surprising. After all, a 5-panel test sounds broad, and it includes “opioids.” Isn't fentanyl an opioid? Unfortunately, that fact alone does not always mean a standard drug test fentanyl screen is included.
In this Article
Learn why standard DOT 5-panel drug tests do not automatically screen for fentanyl, even though fentanyl is an opioid. We explain the differences between DOT and non-DOT testing, compare fentanyl-testing methods, and outline how employers can strengthen their programs without creating compliance problems.
Glossary of Key Terms
-
5-panel drug test: A common drug test panel that screens for five drug classes. In DOT testing, those classes are marijuana metabolites, cocaine metabolites, amphetamines, opioids, and PCP.
-
Analyte: A specific drug, drug metabolite, or other substance that a laboratory tests for in a specimen.
-
DOT drug test: A drug test required under Department of Transportation rules for certain safety-sensitive transportation employees.
-
Expanded drug test panel: A test panel that screens for more substances than a basic panel. Employers may use expanded panels to include drugs such as fentanyl, when allowed by policy and law.
-
Fentanyl: A powerful synthetic opioid that has legitimate medical uses but is also manufactured and distributed illegally. DOT has proposed adding fentanyl to its urine and oral-fluid drug-testing panels.
-
Immunoassay: A common first-step screening method. Some opioid immunoassays may miss synthetic opioids such as fentanyl unless fentanyl-specific testing is ordered.
-
Medical Review Officer (MRO): A licensed physician who reviews laboratory-confirmed drug test results. The MRO considers medical information, communicates with the donor when required, and determines how the result should be reported.
-
Non-DOT drug test: A drug test that is not regulated by DOT rules. Non-DOT employers often have more flexibility, but they still need to follow state law, written policy, and best practices.
-
Norfentanyl: A primary metabolite produced when the body processes fentanyl. DOT has proposed adding norfentanyl to the urine-testing panel, but not to the oral-fluid panel.
-
Opiate: A drug that comes from the opium poppy, such as morphine or codeine.
-
Opioid: A broader term that includes natural, semi-synthetic, and synthetic drugs. Fentanyl is a synthetic opioid.
-
Random drug testing: Unannounced testing of employees selected through a random process. DISA explains that random testing can help deter drug and alcohol use because employees do not know exactly when they may be selected.
-
Reasonable suspicion testing: Testing based on specific, documented observations that suggest an employee may have violated the employer’s drug or alcohol policy. Supervisors should be trained to document objective signs rather than rely on rumors or assumptions.
-
Synthetic Opioid: An opioid produced through chemical processes rather than directly from the opium poppy. Fentanyl is a synthetic opioid.
Why Standard Opioid Testing Can Miss Fentanyl
The terms “opiate” and “opioid” are easy to mix up.
Opiates are drugs that come from the opium poppy, such as morphine and codeine. Opioids, however, are a broader group that includes natural, semi-synthetic, and synthetic substances. Fentanyl falls into the synthetic category.
Here's why that difference matters: A basic opioid screen may detect some opioids, but it may not detect all of them. Fentanyl drug testing usually needs a fentanyl-specific analyte (such as fentanyl or norfentanyl).
Think of it like searching a warehouse. If the search order says, “look for boxes in aisle one,” the team may not check aisle five. Fentanyl can be missed when the test is not designed to find it.
What Does a DOT 5-Panel Drug Test Include?
There is some nuance to the DOT 5-panel fentanyl question for DOT employers.
Again, because current DOT Part 40 language still lists five drug classes for DOT testing and says DOT specimens must not be tested for other drugs, fentanyl is not automatically part of current-day DOT 5-panel test.
At the same time, however, federal rules are moving. DOT published a 2025 Notice of Proposed Rulemaking that proposes adding fentanyl and norfentanyl to DOT drug testing panels (but employers should treat this as proposed until a final rule becomes effective and is incorporated into DOT testing procedures).
Additionally, the Department of Health and Human Services published authorized drug testing panels effective July 7, 2025, some of which do include fentanyl. However, these tests are only to be used for non-DOT drug tests (which means that DOT employers could theoretically use these panels for broad workplace initiatives, but not for safety-sensitive, DOT-regulated positions).
The key point for employers is that DOT and non-DOT testing should never be blended together. DOT tests must follow DOT rules. Non-DOT testing can be more flexible, but it still needs to follow written policy, applicable state law, and sound program design.
Data table
| Testing Scenario |
Fentanyl Included? |
What Employers Should Verify |
|
DOT 5-panel drug test
|
Not automatically under current DOT rule language
|
Current DOT Part 40 requirements and any effective final rule updates
|
|
Non-DOT expanded panel
|
Possible if fentanyl/norfentanyl are ordered
|
Written policy, state law, MRO process, analytes listed by lab
|
|
10-panel drug test
|
Not guaranteed
|
Exact panel configuration and analyte list
|
|
Fentanyl-specific test
|
Yes, when ordered as such
|
Specimen type, cutoff, confirmation process, policy fit
|
Why Employers Are Reconsidering the Standard 5-Panel
Fentanyl risk for DOT employers is not limited to people who knowingly seek fentanyl: The counterfeit-pill issue poses yet another challenge for employers and safety teams.
According to the DEA in 2024, 5 out of every 10 fake pills (marketed and sold by drug dealers as legitimate prescription opioids, such as Percoset and Xanax), contained a potentially lethal dose of fentanyl.
Additionally, Quest Diagnostics reported that, in 2024, fentanyl positivity in the general U.S. workforce was 707% higher in random tests than in pre-employment tests. Quest also reported that 60% of fentanyl-positive specimens were positive for at least one other drug.
That gap matters. A pre-employment fentanyl drug test may help at the hiring stage, but it does not show what happens six months later (due to unsuspecting victims of fake fentanyl pills, or drug use that occurs after hiring).
Which Testing Method Makes Sense for Fentanyl?
If a DOT-regulated employer seeks to expand beyond the standard 5-panel test, the right choice for an addition depends on why the test is being done and what the policy is designed to address.
A fentanyl urine drug test, for instance, is common and may fit many DOT-regulated workplace programs.
A fentanyl oral fluid test may also be useful in some programs; oral fluid collections can be directly observed, which may help reduce certain collection concerns. (DOT added oral fluid testing as an approved methodology in a 2023 final rule, though employers must still follow DOT’s exact program rules when DOT testing applies)
Hair testing can provide a longer lookback period; employers who follow best practices in drug testing have adopted a dual-methodology program with short- and long-term testing.
How to Update a Drug Testing Policy Without Creating Compliance Problems
If you are a DOT-regulated employer and want to start testing for fentanyl, start by separating your policy's DOT and non-DOT language to prevent managers, collectors, and employees from confusing two different programs. DOT-regulated tests must follow DOT rules. Non-DOT tests should be clearly labeled as non-DOT.
Next, work with your Medical Review Officer, legal counsel, and testing partner. Review your current panel, job categories, testing reasons, and state-law limits. Then decide whether fentanyl should be added across the program or only for certain roles.
Training matters too: Your managers should know when post-accident, random, reasonable suspicion, return-to-duty, and follow-up testing apply. They should also know who to call before acting. A strong policy is only useful when the people using it understand it.
The standard 5-panel test still has a place. But it may not be enough for every workplace. And it may not be enough for yours.
Frequently Asked Questions About Fentanyl and Standard Drug Tests
Not usually on a basic opiate screen. Fentanyl is a synthetic opioid, and standard opioid immunoassays may not detect synthetic opioids such as fentanyl unless fentanyl-specific testing is ordered.
Not automatically. A 10-panel test may include more substances than a 5-panel test, but panel names vary by provider and program. Employers should ask whether fentanyl and norfentanyl are listed as specific analytes.
Yes, but only in the right lane. A company may be able to add employer fentanyl screening to a non-DOT program. It should not add fentanyl to DOT specimens unless DOT rules allow it through an effective final rule. Current DOT language still limits DOT testing to five drug classes and says DOT specimens must not be tested for other drugs.
It depends. Urine, oral fluid, and hair each answer different questions (and adopting dual-methodology testing helps answer many of those questions at once). The best choice for your company depends on your policy, job risks, state law, testing reason, and whether the test is DOT or non-DOT.
Because the panel name does not always tell the full story. A standard 5-panel or 10-panel may not include fentanyl unless fentanyl is listed. Employers should review the exact analytes in their program, not just the number of drugs in the panel.
How DISA Can Help
Fentanyl testing does not have to be confusing; the right partner can help you ask the right questions, avoid compliance mistakes, and build a program that supports a safer workplace.
DISA helps employers build drug testing programs that are practical, compliant, and aligned with real workplace risk. We can also review your current panel configurations, separate your DOT and non-DOT policy language, and evaluate whether your fentanyl-specific testing fits your workplace risk, policy, and applicable law.
Additionally, if you manage regulated drivers or other transportation workers, DISA can help you keep DOT drug testing requirements separate from any non-DOT fentanyl testing decisions. Talk to DISA today about reviewing your current configuration.
September 18, 2026
8
min read
